Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Gossamer Bio Inc (GOSS)

Gossamer Bio Inc (GOSS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,154,695
  • Shares Outstanding, K 93,954
  • Annual Sales, $ 0 K
  • Annual Income, $ -234,000 K
  • 60-Month Beta 0.96
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade GOSS with:

Options Overview Details

View History
  • Implied Volatility 111.93% ( +19.97%)
  • Historical Volatility 54.25%
  • IV Percentile 90%
  • IV Rank 24.06%
  • IV High 278.29% on 06/06/22
  • IV Low 59.23% on 12/16/21
  • Put/Call Vol Ratio 0.01
  • Today's Volume 8,587
  • Volume Avg (30-Day) 840
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 27,238
  • Open Int (30-Day) 21,625

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.66
  • Number of Estimates 7
  • High Estimate -0.57
  • Low Estimate -0.84
  • Prior Year -0.80
  • Growth Rate Est. (year over year) +17.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.60 +9.40%
on 10/05/22
14.99 -15.34%
on 09/08/22
-0.96 (-7.03%)
since 09/06/22
3-Month
6.82 +86.07%
on 07/12/22
15.19 -16.49%
on 08/25/22
+4.62 (+57.25%)
since 07/06/22
52-Week
5.64 +125.00%
on 06/16/22
15.19 -16.49%
on 08/25/22
+0.33 (+2.67%)
since 10/06/21

Most Recent Stories

More News
Gossamer Bio Announces Second Quarter 2022 Financial Results and Provides Business Update

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation...

GOSS : 12.69 (+3.25%)
Here's Why Gossamer Bio (GOSS) is a Great Momentum Stock to Buy

Does Gossamer Bio (GOSS) have what it takes to be a top stock pick for momentum investors? Let's find out.

GOSS : 12.69 (+3.25%)
Wall Street Analysts See a 52% Upside in Gossamer Bio (GOSS): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 52.4% in Gossamer Bio (GOSS). While the effectiveness of this highly sought-after metric is questionable, the positive...

GOSS : 12.69 (+3.25%)
Gossamer Bio Announces $120 Million Private Placement Financing

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation...

GOSS : 12.69 (+3.25%)
Gossamer Bio Announces Publication of Key Preclinical Data in the European Respiratory Journal Highlighting Seralutinib’s Potential for the Treatment of PAH

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation...

GOSS : 12.69 (+3.25%)
Wall Street Analysts Believe Gossamer Bio (GOSS) Could Rally 113%: Here's is How to Trade

The mean of analysts' price targets for Gossamer Bio (GOSS) points to an 113.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts...

GOSS : 12.69 (+3.25%)
Gossamer Bio (GOSS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Gossamer Bio (GOSS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions,...

GOSS : 12.69 (+3.25%)
Gossamer Bio Announces First Quarter 2022 Financial Results and Provides Business Update

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation...

GOSS : 12.69 (+3.25%)
Gossamer Bio Announces GB004 Topline Results from Phase 2 SHIFT-UC Study in Ulcerative Colitis and Provides Corporate Update

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation...

GOSS : 12.69 (+3.25%)
Notable Wednesday Option Activity: GOSS, CDLX, JBLU

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Gossamer Bio Inc , where a total volume of 3,766 contracts has been traded thus far...

GOSS : 12.69 (+3.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Gossamer Bio Inc. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutics in the areas of immunology, inflammation and oncology. The company's product pipeline includes GB001, GB002, GB004, GB1275, Autoimmune program and Oncology...

See More

Key Turning Points

3rd Resistance Point 14.85
2nd Resistance Point 14.26
1st Resistance Point 13.48
Last Price 12.69
1st Support Level 12.10
2nd Support Level 11.51
3rd Support Level 10.73

See More

52-Week High 15.19
Last Price 12.69
Fibonacci 61.8% 11.54
Fibonacci 50% 10.42
Fibonacci 38.2% 9.29
52-Week Low 5.64

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar